Profiles

Barbara de Graaff

UTAS Home Dr Barbara de Graaff
Barbara de Graaff pic

Barbara de Graaff

Postdoctoral Research Fellow (Health Economics)

Medical Science Precinct, Hobart CBD Campuses

61 3 6226 4262 (phone)

barbara.degraaff@utas.edu.au

Dr Barbara de Graaff is a Postdoctoral Research Fellow in health economics at the Menzies Institute for Medical Research. Her main interests are the health economic aspects of clinical medicine and early interventions, and health equity. She recently completed her PhD on the health economic aspects of hereditary haemochromatosis, a common genetic condition that can result in liver and heart disease.

Biography

Barbara completed her PhD at the Menzies Institute for Medical Research, University of Tasmania, where she investigated the health economic aspects of hereditary haemochromatosis. This work included the first quantification of the economic burden associated with hemochromatosis.

Prior to commencing her PhD, Barbara worked as a research fellow at the School of Psychology, University of Tasmania. This work focused on injecting drug use and harm reduction interventions for people who inject drugs.   Barbara has also held clinical and research roles with Turning Point Alcohol and Drug Centre, Melbourne, and Alcohol and Drug Services, Queensland Health.

Career summary

Qualifications

PhD: The Health Economics Aspects of Hereditary Haemochromatosis University of Tasmania Australia 2016

Memberships

Professional practice

Australian Health Economics Society

International Health Economics Association

Teaching

Teaching responsibility

Introduction to Health Economics

Health economic evaluations

Research Appointments

Board member of the Australian Health Economics Society

Convenor of the Australian Health Economics Society Doctoral Workshop

Member of the International Society for Pharmacoeconomics and Outcomes Research

View more on Ms Barbara de Graaff in WARP

Research Themes

Barbara’s research aligns with the University’s Better Health Theme. Since completing her PhD, she has been working with the NHMRC-funded Centre for Research Excellence- Pulmonary Fibrosis. This work has involved leading the health economic evaluation of idiopathic pulmonary fibrosis under the supervision of Professors Andrew Palmer and Haydn Walters. In addition, Barbara is leading the development of a patient-centred early intervention strategy for detection of primary hepatocellular carcinoma; and evaluating the cost-effectiveness of new hepatitis C treatments.

Recently, Barbara has evaluated aspects of after-hours primary care.  She led a project for Primary Health Tasmania, evaluating provision of after-hours primary care in Tasmania. In collaboration with Professor Mark Nelson, she evaluated the impact of the new business model of after-hours home visiting doctors on Medicare, culminating in a public submission to Medicare.

Awards

2017 University of Tasmania Career Development Scholarship

Visiting Scholar at the Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, 2017

Vice Chancellor’s Leadership Awards, 2013

Current projects

1. Evaluating the quality of life and health economic outcomes associated with idiopathic pulmonary fibrosis

2. Developing patient centred screening tools for hepatocellular carcinoma screening

3. Evaluating the clinical and health economic outcomes associated with new generation hepatitis C drugs

Fields of Research

  • Public Health and Health Services (111799)
  • Health, Clinical and Counselling Psychology (170106)
  • Health Economics (140208)
  • Health Information Systems (incl. Surveillance) (111711)
  • Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology) (170101)
  • Primary Health Care (111717)
  • Health and Community Services (111708)
  • Gastroenterology and Hepatology (110307)
  • Health Care Administration (111709)
  • Infectious Diseases (110309)
  • Psychology and Cognitive Sciences (179999)
  • Medical and Health Sciences (119999)
  • Haematology (110202)
  • Clinical Pharmacology and Therapeutics (111502)
  • Rheumatology and Arthritis (110322)
  • Clinical Sciences (110399)
  • Paediatrics (111403)
  • Pharmacology and Pharmaceutical Sciences (111599)
  • Health Promotion (111712)

Research Objectives

  • Substance Abuse (920414)
  • Public Health (excl. Specific Population Health) (920499)
  • Respiratory System and Diseases (incl. Asthma) (920115)
  • Evaluation of Health Outcomes (920204)
  • Health Policy Evaluation (920208)
  • Infectious Diseases (920109)
  • Health and Support Services (920299)
  • Blood Disorders (920101)
  • Expanding Knowledge in Psychology and Cognitive Sciences (970117)
  • Specific Population Health (excl. Indigenous Health) (920599)
  • Health (929999)
  • Health Policy Economic Outcomes (920207)
  • Skeletal System and Disorders (incl. Arthritis) (920116)
  • Cancer and Related Disorders (920102)
  • Expanding Knowledge in the Medical and Health Sciences (970111)
  • Mental Health Services (920209)
  • Preventive Medicine (920412)
  • Clinical Health (Organs, Diseases and Abnormal Conditions) (920199)
  • Behaviour and Health (920401)
  • Palliative Care (920211)
  • Cardiovascular System and Diseases (920103)
  • Health Education and Promotion (920205)
  • Fixed Line Telephone Networks and Services (890102)

Publications

Total publications

53

Journal Article

(12 outputs)
YearCitationAltmetrics
2018Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, et al., 'Haemochromatosis', Nature Reviews. Disease Primers, 4 Article 18016. ISSN 2056-676X (2018) [Refereed Article]

DOI: 10.1038/nrdp.2018.16 [eCite] [Details]

Citations: Scopus - 3Web of Science - 2

Tweet

2018de Graaff B, Yee KC, Clarke P, Palmer A, 'Uptake of and expenditure on direct-acting antiviral agents for Hepatitis C treatment in Australia', Applied Health Economics and Health Policy pp. 1-8. ISSN 1175-5652 (2018) [Refereed Article]

DOI: 10.1007/s40258-018-0392-8 [eCite] [Details]

Citations: Web of Science - 1

Co-authors: Yee KC; Palmer A

Tweet

2017de Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ, 'Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study', Australian Health Review, 41, (3) pp. 254-267. ISSN 0156-5788 (2017) [Refereed Article]

DOI: 10.1071/AH15188 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Neil A; Sanderson K; Yee KC; Palmer AJ

Tweet

2017de Graaff B, Neil A, Si L, Yee KC, Sanderson K, et al., 'Cost-effectiveness of different population screening strategies for hereditary haemochromatosis in Australia', Applied Health Economics and Health Policy, 15, (4) pp. 521-534. ISSN 1175-5652 (2017) [Refereed Article]

DOI: 10.1007/s40258-016-0297-3 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Neil A; Si L; Yee KC; Sanderson K; Palmer AJ

Tweet

2017de Graaff B, Nelson M, Neil A, 'Up, up and away: The growth of after-hours MBS claims', Australian Family Physician, 46, (6) pp. 407-411. ISSN 0300-8495 (2017) [Refereed Article]

PMID: 28609598 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Nelson M; Neil A

Tweet

2017de Graaff B, Si L, Neil AL, Yee KC, Sanderson K, et al., 'Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model', PharmacoEconomics - Open, 1, (1) pp. 37-51. ISSN 2509-4254 (2017) [Refereed Article]

DOI: 10.1007/s41669-016-0005-0 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Si L; Neil AL; Yee KC; Sanderson K; Palmer AJ

Tweet

2016Neil A, de Graaff B, 'Need, want and demand: What is really happening with low-acuity presentations?', Emergency Medicine Australasia pp. 1-2. ISSN 1742-6731 (2016) [Letter or Note in Journal]

DOI: 10.1111/1742-6723.12591 [eCite] [Details]

Co-authors: Neil A

Tweet

2016de Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ, 'Quality of life utility values for hereditary haemochromatosis in Australia', Health and Quality of Life Outcomes, 14, (1) Article 31. ISSN 1477-7525 (2016) [Refereed Article]

DOI: 10.1186/s12955-016-0431-9 [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Co-authors: Neil A; Sanderson K; Yee KC; Palmer AJ

Tweet

2015de Graaff B, Neil A, Sanderson K, Si L, Yee KC, et al., 'A systematic review and narrative synthesis of health economic studies conducted for hereditary haemochromatosis', Applied Health Economics and Health Policy, 13, (5) pp. 469-483. ISSN 1175-5652 (2015) [Refereed Article]

DOI: 10.1007/s40258-015-0189-y [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Co-authors: Neil A; Sanderson K; Si L; Yee KC; Palmer AJ

Tweet

2014Si L, Winzenberg TM, de Graaff B, Palmer AJ, 'A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions', Osteoporosis International, 25, (8) pp. 1987-1997. ISSN 0937-941X (2014) [Refereed Article]

DOI: 10.1007/s00198-014-2636-2 [eCite] [Details]

Citations: Scopus - 30Web of Science - 27

Co-authors: Si L; Winzenberg TM; Palmer AJ

Tweet

2012Patel PK, Patel RP, Brandon S, McLean S, Bruno R, et al., 'Effects of Filtration on the Presence of Particulate and Oxycodone Content of Injections Prepared from Crushed OxyContin® Tablets', Current Drug Safety, 7, (3) pp. 218-224. ISSN 1574-8863 (2012) [Refereed Article]

DOI: 10.2174/157488612803251298 [eCite] [Details]

Citations: Scopus - 9

Co-authors: Patel RP; Brandon S; McLean S; Bruno R

Tweet

2009McLean SR, Bruno RB, Brandon S, de Graaff B, 'Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets', Harm Reduction Journal, 6, (37) EJ ISSN 1477-7517 (2009) [Refereed Article]

DOI: 10.1186/1477-7517-6-37 [eCite] [Details]

Citations: Scopus - 17Web of Science - 15

Co-authors: McLean SR; Bruno RB; Brandon S

Tweet

Conference Publication

(19 outputs)
YearCitationAltmetrics
2016de Graaff BL, Neil A, Sanderson K, Yee KC, Palmer AJ, 'PND9 - An Australian National Cost of Illness Study For Hereditary Haemochromatosis', Value in Health, pp. A874, 19 (7). ISSN 1098-3015 (2016) [Conference Extract]

DOI: 10.1016/j.jval.2016.08.344 [eCite] [Details]

Co-authors: Neil A; Sanderson K; Yee KC; Palmer AJ

Tweet

2016de Graaff BL, Si L, Neil A, Yee KC, Sanderson K, et al., 'PND10 - Cost-Effectiveness of Population Screening for Haemochromatosis In Australia: A State-Transition Model', Value in Health, pp. A874-A875, Vol 19 (7). ISSN 1098-3015 (2016) [Conference Extract]

DOI: 10.1016/j.jval.2016.08.345 [eCite] [Details]

Co-authors: Si L; Neil A; Yee KC; Sanderson K; Palmer AJ

Tweet

2015de Graaff BL, Neil A, Sanderson K, Yee KC, Palmer A, 'The impact of increasing severity of hereditary haemochromatosis on health state utility values', Value in Health, pp. A300, Vol 18, A1-A307. ISSN 1098-3015 (2015) [Conference Extract]

[eCite] [Details]

Co-authors: Neil A; Sanderson K; Yee KC; Palmer A

2012de Graaff B, Bruno RB, 'The correlates of financial strain amongst people who inject drugs', Drug and Acohol Review, 18-21 November 2012, Melbourne, Victoria, pp. 54. ISSN 0959-5236 (2012) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2012de Graaff B, Bruno RB, 'Experience of non-viral injecting-related injuries and diseases amongst people who regularly inject drugs', Drug and Alcohol Review, 18-21 November 2012, Melbourne, Victoria, pp. 55. ISSN 0959-5236 (2012) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2011Wake C, Bruno RB, Siddall D, de Graaff B, Donaldson F, et al., 'Health and Well-Being in Tasmanian Prisoners With and Without Hepatitis C Antibodies', Drug and Alcohol review, 13-16 November 2011, Hobart, Australia, pp. 88. ISSN 0959-5236 (2011) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2011de Graaff B, Bruno RB, Wake C, 'NPS provision in prisons: Time to embrace the evidence', Drug and Alcohol Review, 13-16 November 2011, Hobart, Australia, pp. 24. ISSN 0959-5236 (2011) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2010Cassar J, de Graaff B, Phillips B, Nielsen S, Bruno RB, et al., 'Over the counter codeine use by people who inject drugs regularly in Australia', Drug and Alcohol Review, 28 November-1 December 2010, Canberra, Australia, pp. A11. (2010) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2010Ebert RH, Bruno RB, Matthews AJ, de Graaff B, 'Predictors of sub-clinical paranoia among methamphetamine consumers', Drug and Alcohol Review, 28 November-1 December 2010, Canberra, Australia, pp. A24. (2010) [Conference Extract]

[eCite] [Details]

Co-authors: Ebert RH; Bruno RB; Matthews AJ

2010McLean SR, Brandon S, Bruno RB, de Graaff B, Patel RP, 'Reducing harm from pharmaceutical opioid injection: The importance and effectiveness of filters', Drug and Alcohol Review, 28 November -1 December 2010, Canberra, Australia, pp. A51. (2010) [Conference Extract]

[eCite] [Details]

Co-authors: McLean SR; Brandon S; Bruno RB; Patel RP

2010McLean SR, Brandon S, de Graaff B, Bruno RB, Patel RP, 'Injecting OxyContin: What is the harm reduction eveidence?', Proceedings of ATDC 2010, 18-20 October 2010, Hobart, pp. 1. (2010) [Conference Extract]

[eCite] [Details]

Co-authors: McLean SR; Brandon S; Bruno RB; Patel RP

2010de Graaff B, Bruno RB, 'Old fits, new fits: Re-use of injecting equipment amongst a sample of regular injectiing drug users in Tasmania', Drug and Alcohol Review, 28 November-1 December 2010, Canberra, Australia, pp. A17-18. (2010) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2010de Graaff B, Bruno RB, 'Alprazolam use in Tasmania: Is policy change kicking goals or behinds?', Drug and Alcohol Review, 28 November-1 December 2010, Canberra, Australia, pp. A17. (2010) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2009Bruno RB, Gomez R, Fry C, Stoove M, de Graaff B, 'The blood borne virus transmission risk assessment questionnaire (short version): Can it identify risk equivalently for heroin, methamphetamine and pharmaceutical opioid injectors?', Drug and Alcohol Review, 1-4 November 2009, Darwin, pp. A6-A7. (2009) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB; Gomez R

2009Bruno RB, McLean SR, Brandon S, de Graaff B, Murray N, 'Injecting MS Contin: What is the harm reduction evidence?', Drug and Alcohol Review, 1-4 November 2009, Darwin, pp. A69. (2009) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB; McLean SR; Brandon S

2009Bruno RB, de Graaff B, 'Bumps, bruises and benzos: Factors associated with accidents amongh regular injecting drug users', Drug and Alcohol Review, 1-4 November 2009, Darwin, pp. A6. (2009) [Conference Extract]

[eCite] [Details]

Co-authors: Bruno RB

2008Bruno RB, Murray N, McLean SR, de Graaff B, Brandon S, 'Filtering pharmaceutical opioids for injection: What methods are being used and how effective are they?', APSAD, 23-26 November 2008, Sydney, NSW, pp. 86. (2008) [Conference Edited]

[eCite] [Details]

Co-authors: Bruno RB; McLean SR; Brandon S

2008Bruno RB, de Graaff B, 'Pull the other one: Effects of the prescription restriction level for benzodiazepines in an isolated drug market', APSAD, 23-26 November 2008, Sydney, NSW, pp. 37. (2008) [Conference Edited]

[eCite] [Details]

Co-authors: Bruno RB

2008de Graaff B, Bruno RB, Snidicich N, 'Pharmaceutical opioid injection in high and low heroin availability jurisdictions: the who and why', APSAD, 23-26 November 2008, Sydney, NSW, pp. 77. (2008) [Conference Edited]

[eCite] [Details]

Co-authors: Bruno RB

Contract Report, Consultant's Report

(16 outputs)
YearCitationAltmetrics
2017de Graaff B, Makin J, Neil A, Nelson M, 'Tasmanian After-Hours Primary Care: Evaluation of the GP Assist Service 2017', Primary Health Tasmania (2017) [Contract Report]

[eCite] [Details]

Co-authors: Neil A; Nelson M

2016Neil A, de Graaff B, Nelson M, Chappell K, Palmer A, et al., 'Tasmanian After-Hours Primary Care Service Innovations: A Report in Three Parts', Primary Health Tasmania (2016) [Contract Report]

[eCite] [Details]

Co-authors: Neil A; Nelson M; Chappell K; Palmer A; Sanderson K

2015Peacock A, de Graaff B, Bruno RB, 'Tasmanian drug trends 2014. Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 131', National Drug and Alcohol Research Centre, Australia, 131 (2015) [Contract Report]

[eCite] [Details]

Co-authors: Peacock A; Bruno RB

2013de Graaff B, Bruno RB, 'Tasmania Drug Trends 2012: Findings from the Illicit Drug Reporting System (IDRS)', Australian Government Department of Health and Ageing, 77 (2013) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

2012de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2011: Findings from the Illicit Drug Reporting System (IDRS)', Australian Government Department of Health and Ageing, Sydney, 77 (2012) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

Tweet

2011de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2010: Findings from the Illicit Drug Report System (IDRS)', Australian Government Department of Health and Aging, Sydney, 59 (2011) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

Tweet

2010de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2009: Findings from the Illicit Drug Reporting System (IDRS)', National Drug and Alcohol Research Centre, Sydney, 41 (2010) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

Tweet

2010de Graaff B, Bruno RB, 'The Health and Wellbeing of a Group of Tasmanian Regular Injecting Drug Users', National Drug and Alcohol Research Centre (2010) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

2009de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2008: Findings from the Illicit Drug Reporting System (IDRS)', Australian Government Department of Health and Ageing, Sydney (2009) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

2008Black E, Roxburgh A, Degenhardt L, Bruno RB, Campbell G, et al., 'Australian Drug Trends 2007: Findings from the Illicit Drug Reporting System', Australian Government Department of Health and Ageing, Sydney, 978-0-7334-2625-4 (2008) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

Tweet

2008de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2007: Findings from the Ilicit Drug Reporting System (IDRS)', Australian Government Department of Health and Ageing, Sydney (2008) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

2007Bruno RB, Ong SY, de Graaff B, 'Indicators of Drug Use in Tasmania', Tasmanian State Government - Department of Health and Human Services (2007) [Consultants Report]

[eCite] [Details]

Co-authors: Bruno RB; Ong SY

2007O'Brien S, Black E, Degenhardt L, Roxburgh A, Campbell G, et al., 'Australian Drug Trends 2006: Findings from the Illicit Drug Reporting System', Australian Government Department of Health and Ageing; National Drug Law Enforcement Research Fund, 60 (2007) [Contract Report]

[eCite] [Details]

2007de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2006: Findings from the Illicit Drug Reporting System (IDRS)', Australian Government Department of Health and Aging; National Drug Law Enforcement Research Fund, 273 (2007) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

2007de Graaff B, Bruno RB, 'Self-reported mental health problems amongst regular injecting drug users interviewed in the IDRS', Australian Government Department of Health and Aging (2007) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

2007de Graaff B, Bruno RB, 'Tasmanian Drug Trends 2006: Findings from the Illicit Drug Reporting System and Extension Study (IDRS-E)', Tasmanian State Government Department of Health and Human Services (2007) [Contract Report]

[eCite] [Details]

Co-authors: Bruno RB

Thesis

(1 outputs)
YearCitationAltmetrics
2016de Graaff B, 'The Health Economics of Haemochromatosis' (2016) [PhD]

[eCite] [Details]

Other Public Output

(5 outputs)
YearCitationAltmetrics
2017de Graaff B, Nelson MR, 'After-hours GP home visits strain the budget (and don't help emergency departments)', The Conversation (2017) [Magazine Article]

[eCite] [Details]

Co-authors: Nelson MR

Tweet

2016Neil A, de Graaff B, Chappell K, Sanderson K, Palmer A, et al., 'What Value GP Assist? The comparative benefits of, and satisfaction with GP Assist in Residential Aged Care Facilities and General Practice in Rural and Urban Tasmania', Department of Health and Human Services, Tasmanian Government (2016) [Government or Industry Research]

[eCite] [Details]

Co-authors: Neil A; Chappell K; Sanderson K; Palmer A; Nelson M

2014Peacock A, de Graaff B, Bruno RB, 'Barriers to Harm Reduction: Heating and Filtration of Oxycodone Tablets Prior to Intravenous Use by People Who Inject Drugs in Australia', Drug Trends Bulletin, National Drug and Alcohol Research Centre, University of New South Wales, Australia, Australia, April 2014 (2014) [Government or Industry Research]

[eCite] [Details]

Co-authors: Peacock A; Bruno RB

2014de Graaff B, Peacock A, Bruno RB, 'Tasmanian drug trends 2013. Findings from the Illicit Drug Reporting System (IDRS)', Australian Drug Trends Series No. 113, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, pp. 1-194. (2014) [Government or Industry Research]

[eCite] [Details]

Co-authors: Peacock A; Bruno RB

2011de Graaff B, 'Push to fight jail hepatitis', The Mercury, Hobart, 28 November 2011, p. 13. (2011) [Newspaper Article]

[eCite] [Details]

Grants & Funding

Funding Summary

Number of grants

4

Total funding

$519,979

Projects

Evaluation of the Tasmanian Elective Surgery Panel Project (2019)$9,980
Description
In 2015, the Tasmanian State Government allocated additional funds to reduce the public hospital elective surgery waiting lists. A subset of waitlisted patients was fast-tracked for elective surgery to hospitals in Tasmania and Victoria. This project will evaluate the outcomes of this initiative.
Funding
Royal Hobart Hospital Research Foundation ($9,980)
Scheme
Grant-Incubator
Administered By
University of Tasmania
Research Team
de Graaff B; Song J; Hensher M; Campbell JA; Glading JA; Palmer AJ
Year
2019
Lead Support Coordinator Service (LSCS) Evaluation (2018)$99,999
Description
The LSCS trials a new model of coordinated care for clients with complex needs . Three community service organisations, Australian Red Cross, Mission Australia and Baptcare will employ 12 Lead service. Coordinators to provide the service to a maximum of 30 Tasmanians with multiple service needs. Clients will work with the coordinator to identify needs and match them to available services. The evaluation aims to test if this model of coordination leads to better health and wellbeing outcomes for the clients and more efficient and cost effective service delivery.
Funding
Department of Health and Human Services Tasmania ($99,999)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Doherty BT; Nash RE; de Graaff B; Julian RD; Campbell JA; Palmer AJ
Year
2018
Reducing the Burden of Liver Cancer for Tasmanians (2018)$350,000
Description
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is the third leading cause of cancer deaths internationally. It occurs most commonly amongst patients with cirrhosis of the liver, which is often caused by chronic infections with the hepatitis B and/or hepatitis C viruses. The clinical outcomes for patients diagnosed with HCC are highly dependent of the stage at which it is detected. Late detection is associated with significant morbidity and mortality. If detected early, HCC is potentially curable.Screening programs have been suggested to increase the rate of early diagnosis for at-risk groups. In Australia, current guidelines recommend HCC screening for all patients with cirrhosis, regardless of liver disease severity or aetiology. Screening consists of 6-monthly liver ultrasound and alpha-fetoprotein tests. Uptake of screening for HCC is very low in Australia, evidenced by the 5-year survival rate of just 17%. The aims of this project are to a) evaluate current uptake and adherence of HCC screening across Tasmania, b) develop strategies aimed at supporting at-risk patients to participate in regular HCC screening, c) evaluate the cost-effectiveness of screening interventions, and d) assess the effectiveness of new treatments for hepatitis C in reducing the rate of HCC in Tasmania.
Funding
Sefton Bottomley Liver Cancer Bequest ($350,000)
Scheme
Donation - Individual
Administered By
University of Tasmania
Research Team
de Graaff B; Palmer AJ; Yee KC; Cocker FM
Year
2018
GP Assist (2017)$60,000
Description
Ongoing evaluation of the value-for-money of the GP Assist after-hours telephone support service for Primary Health Tasmania.
Funding
Primary Health Tasmania ($60,000)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
de Graaff B; Neil A; Nelson MR
Year
2017

Research Supervision

Current

5

Current

DegreeTitleCommenced
PhDHealth Economics of Obesity in Adult Population in Ghana2017
PhDCost-Effectiveness of Formal and Informal Prevention and Treatment Against Upper Respiratory Tract Infections Among Rural Residents in Anhui, China2017
PhDAssessing the Burden and Economic Impact of IPF in Australia2018
MastersUnderstanding Primary Liver Cancer in Tasmania2018
PhDMaximising Appropriate use of Emergency Care by People with Mental Illness: Current use and Opportunity for Intervention2018